Research center
What the evidence actually says about peptides
1214 entries. Filter by evidence type, peptide, or outcome.
Showing 48 of 1064 entries
- Human
RCT · Ongoing · on Testagen
Product Transference Study of Testagen™ TDS®-Testosterone
ClinicalTrials.gov
This study will assess the potential of Testagen® TDS-Testosterone to enable transfer of Testosterone to females coming in contact with skin to which Testagen® TDS-Testosterone has been applied and the potential of product to raise serum androgen levels in those women.
View trial → - Human
on Oxytocin
Salivary oxytocin and testosterone in empathic stress responding: a pilot study
Heilmann K, Walter M, Engert V. · Stress (Amsterdam, Netherlands)
Suffering the stress of others (termed empathic stress or stress contagion) may affect an individual's health and well-being.
Read on DOI → - Human
Cohort · Ongoing · on MOTS-c
Mitophagy and Mitochondrial DNA Dynamics During Ramadan Dry Fasting vs 16:8 Time-Restricted Feeding
ClinicalTrials.gov
This study investigates how different types of fasting affect cell health, specifically focusing on how mitochondria (the energy-producing parts of cells) are cleared and renewed.
View trial → - Human
on MGF
Multimodal graph-based fusion via image descriptions for few-shot open-set recognition
Huang X, Choi SH. · Neural networks : the official journal of the International Neural Network Society
Few-shot open-set recognition (FSOR) presents unique challenges due to the limited labeled samples and the presence of unknown classes during inference.
Read on DOI → - Human
on Kisspeptin-10
Kisspeptin-10/basal LH ratio improves differentiation of central precocious puberty and premature thelarche
Banerjee AA, Bhanarkar SR, Kashikar S, Keshwani R, Walia S, Kavya DR, Bombe S, Pande S, Modi DN, Pathak BR, Joshi B, Tandon D, Patil A, Begum S, Mahale SD, Rao S, Surve SV. · Clinica chimica acta; international journal of clinical chemistry
Background Distinguishing idiopathic central precocious puberty (ICPP) from premature thelarche (PT) remains a clinical challenge and often necessitates GnRH stimulation testing.
Read on DOI → - Human
Review · on Glutathione
AA-Induced Lipid Peroxidation at the Center of Tumor Cell Apoptosis and Ferroptosis
Das UN. · Reviews of physiology, biochemistry and pharmacology
Polyunsaturated fatty acids (PUFAs), especially gamma-linolenic acid (GLA), arachidonic acid (AA), eicosapentaenoic acid (EPA), and docosahexaenoic acid (DHA), can block HMG-CoA reductase activity and thus decrease cholesterol synthesis/formation.
Read on DOI → - Human
RCT · Ongoing · on GHK-Cu
Two-Part Study of the Effects of the X39 Patch on Circulating GHK and GHK-Cu Levels in Healthy Adults
ClinicalTrials.gov
The goal of this clinical trial is to investigate GHK and GHK-Cu blood levels pre- and post-intervention in healthy adults, and to investigate the efficacy of X39 patch on GHK and GHK-Cu blood levels in healthy adults compared to a placebo.
View trial → - Human
RCT · Ongoing · on BPC-157
Impact of BPC-157 on Recovery Following Rotator Cuff Repair Surgery
ClinicalTrials.gov
This study is a randomized, double-blind, placebo-controlled pilot trial investigating the effects of BPC-157 on tendon healing and functional recovery following arthroscopic rotator cuff repair (aRCR).
View trial → - Human
Cohort · 2026 · on hCG
Evaluation of the Role of Luteinizing Hormone (LH) and Human Chorionic Gonadotropin (hCG) in Adult Patients Undergoing Assessment for Endocrine Disorders
ClinicalTrials.gov
Hormones are chemical messengers that help regulate many functions in the body. As women go through menopause, and as men age, levels of certain reproductive hormones change significantly. One of these hormones, luteinizing hormone (LH), increases substantially after menopause and may also rise in some men.
View trial → - Human
Cohort · 2026 · on hCG
Costa Rican Registry of IL-23 Inhibitors in Psoriatic Disease
ClinicalTrials.gov
The goal of this observational registry study is to evaluate the real-world effectiveness and safety of IL-23 inhibitors in patients with psoriatic disease (psoriasis and/or psoriatic arthritis) treated in Costa Rica.
View trial → 2026 · on hCG
When to test: defining the earliest reliable time for pregnancy detection and its prognostic value after frozen embryo transfer
Xiao H, Shang X, Ouyang G, Fang Y, Zhao D, Niu Y, Liu Y, Zou J, Li N, Wang Z, Liu L, Wei D. · AJOG global reports
Open source →- Human
2026 · on hCG
Low-Level Cerebrospinal Fluid β-hCG Elevation in Patients with Pineal Parenchymal Tumors: A Four-Case Series and Diagnostic Caution
He Y, Tong C, Li Y, Jiang T, Li B. · Journal of clinical medicine
Background : Pineal region tumors (PRTs) are rare and biologically heterogeneous neoplasms with overlapping clinical and radiological features.
Read on DOI → 2026 · on hCG
Biochemical-sonographic Correlations in First-trimester Screening for Foetal Aneuploidy: A Cross-sectional Study from Eastern India
Rani K, Keshari JR, Raj KH, Kumari R, Prasad D, Prabhakar P. · Annals of African medicine
Background Aneuploidy screening constitutes an essential component of routine prenatal care worldwide, which is done by ultrasonography during the first trimester.
Read on DOI →- Human
2026 · on hCG
Progesterone levels on hCG trigger day and neonatal outcomes in fresh embryo transfers: a retrospective threshold analysis of GnRH antagonist versus agonist long protocols
Wu J, Zhang H, Huang J, Hai L, Liang X, Liu D, Zhou J, Li X, He Y, Wang X. · Frontiers in endocrinology
Background Elevated progesterone levels on the day of human chorionic gonadotropin (hCG) trigger are known to adversely affect pregnancy outcomes in fresh embryo transfer (fET) cycles, but their impact on neonatal outcomes remains poorly understood.
Read on DOI → - Animal
Cohort · 2026 · on hCG
Buserelin Improves Ovulation-Embryo Synchrony Compared With hCG After eCG-Induced Superovulation in Donor Sows
Lopez-Jara A, Garcia-Canovas M, Gonzalez-Ramiro H, Gil MA, Cuello C, Rodriguez-Martinez H, Parrilla I, Martinez EA. · Reproduction in domestic animals = Zuchthygiene
This study directly compares hCG and buserelin as ovulation-inducing agents following eCG-based superovulation in weaned donor sows, focusing on their practical impact on ovulation-embryo synchrony under field conditions.
Read on DOI → Case report · 2026 · on hCG
Pulmonary Epithelioid Trophoblastic Tumor Without Demonstrable Uterine Involvement: A Case Report and Literature Review Highlighting Diagnostic Challenges and Multidisciplinary Management
Journal of clinical medicine
Open source →2026 · on hCG
Pregnancy testing prior to iodine-131 thyroid therapy: a literature review of current recommendations
Sozio S, Cohen D, Raynor W, Kempf J. · EJNMMI reports
Open source →Case report · 2026 · on hCG
Choriocarcinoma at an Abdominal Wall Cesarean Scar: Recurrence After Multi-Line Chemotherapy and Exploration of Salvage Therapy
Xu S, Huang C, Wang M, Wu W, Zhou J. · International journal of women's health
Choriocarcinoma arising at an abdominal wall cesarean scar is not only exceedingly rare and diagnostically challenging but also represents a therapeutic dilemma, particularly when it becomes chemoresistant or relapses after multi-line chemotherapy.
Read on DOI →2026 · on hCG
Optimization of Pregnancy Testing in the Emergency Department: A Quality Improvement Initiative
Holstege M, Mukubwa N, Smith M, Layng T, Wendel S. · American journal of medical quality : the official journal of the American College of Medical Quality
Background At our institution, a review of emergency department pregnancy testing identified excess use of serum quantitative (quant) human chorionic gonadotropin (hCG) when only a binary result was clinically indicated. Additionally, we observed delays in point-of-care (POCT) urine hCG turnaround time.
Read on DOI →2026 · on hCG
Evaluation and performance of the β-hCG discriminatory zone and targeted ultrasound findings for early pregnancy diagnosis in a high-risk population: a retrospective cohort study at a US safety-net hospital
Cherouveim P, Tuli S, Cetin E, Garner J, Fayyaz T, Soylu M, Lachance J, Merida Reyes MA, Kobold R, Akinpeloye A. · BMJ open
Read on DOI →2026 · on Vilon
Secondary-Amine Relay Enables Lysine-Directed Multicomponent Functionalization of Peptides
Ren C, Zhang M, Jiang T, Wan F, Lv Y, Yang L, Li C. · JACS Au
Multicomponent reactions provide powerful modularity for peptide functionalization, but their application to lysine residues remains limited by the low efficiency of direct primary-amine-based activation pathways under peptide-compatible conditions.
Read on DOI →- Human
Review · 2026 · on Vilon
Epitalon and Epithalamin: A Narrative Review of Mechanistic, Preclinical, and Clinical Evidence
Jain A, Gallacher DM, Issa MA, Deer TR, Yong RJ, Diwan S, Lee W, Sayed D, Amirdelfan K, Robinson CL. · International journal of molecular sciences
Epitalon (Ala-Glu-Asp-Gly) is a synthetic tetrapeptide developed from the amino-acid composition of epithalamin, a chemically distinct pineal-derived polypeptide preparation.
Read on DOI → - Human
Case report · 2026 · on Vasoactive Intestinal Peptide (VIP)
Vasoactive Intestinal Peptide (VIP)-Secreting Neuroblastic Tumors in Children Presenting With Chronic Secretory Diarrhea: A Report of Two Cases
Barbar M, Sultan I, Alrifaai A, Al-Dabbagh A, Halalsheh H. · Cureus
Vasoactive intestinal peptide (VIP)-secreting neuroblastic tumors are rare pediatric neoplasms that may present with chronic secretory diarrhea prior to tumor detection, posing significant diagnostic and therapeutic challenges.
Read on DOI → - Human
Review · 2026 · on Tirzepatide + Retatrutide
Emerging role of GLP-1 mono, dual, and triple agonists in the management of MASH-related fibrosis
Tavaglione F, Loomba R. · Cell reports. Medicine
Recent therapeutic advances have resulted in US Food and Drug Administration (FDA) approval of the first pharmacological agents-resmetirom and semaglutide-for advanced metabolic dysfunction-associated steatohepatitis (MASH) without cirrhosis, reshaping the therapeutic landscape of the disease.
Read on DOI → - Human
Review · 2026 · on Tirzepatide + Retatrutide
Evolution of incretin-based therapies: From GLP-1 monotherapy to dual and triple agonists: A new era in metabolic therapy
Gupta M, Shukla J. · The Indian journal of medical research
Incretin-based therapies have revolutionised the management of metabolic disorders, transitioning from DPP-4 inhibitors to advanced GLP-1 receptor agonists (GLP-1RAs) and next-generation dual and triple agonists.
Read on DOI → Review · 2026 · on Tirzepatide + Retatrutide
Recent Studies on the Effectiveness and Safety of Anti-Obesity Medications: A Scoping Review
Puspitasari IM, Putra DS, Deliyana AN, Adiputri NI, Octovia LI, Paramita SA, Sinuraya RK. · Diabetes, metabolic syndrome and obesity : targets and therapy
Obesity remains a major global public health challenge associated with increased morbidity, mortality, and reduced quality of life, necessitating effective treatment strategies beyond lifestyle modifications.
Read on DOI →2026 · on Tirzepatide + Retatrutide
Beyond weight loss: Preserving muscle health in the incretin era
Imaizumi T, Yabe D. · Journal of diabetes investigation
Read on DOI →- Human
2026 · on Tirzepatide + Retatrutide
Incretin-Based Dual and Triple Agonists in Overweight or Obese Individuals: A Systematic Review and Meta-Analysis
Chan ZH, Omar AS, Gill K, Volucke G, Azhar MM, Haleem SM, Sia JE, Rahman OU, Ahmad M, Shahid N, Gardezi SA, Joseph KV, Behary Paray N, Zulfiqar E. · Cardiology in review
Incretin-based dual and triple agonists have emerged as effective options for obesity management, offering enhanced weight loss through multi-receptor agonism. However, data on their efficacy and safety remain limited.
Read on DOI → 2026 · on Tirzepatide + Retatrutide
Efficacy and Safety of Dual GLP-1/Glucagon Receptor Agonism in Overweight and Obesity: A Class-Specific Systematic Review and Meta-Analysis
Amjad MM, Khan MM, Sarwar F, Ali A, Ali M, Bakhash F, Abid H, Ibrahim F, Mustafa K, Ali DE, Fayyaz MMN, Hassan H, Mian SM, Yaseen M, Qamar I, Khan AH, Ullah S, Khan BW. · Diabetes, obesity & metabolism
Background Dual glucagon-like peptide-1/glucagon receptor (GLP-1/GCGR) agonists represent a novel obesity treatment class, but existing meta-analyses often conflate them with GIP-containing agents (tirzepatide, retatrutide) or restrict analysis to one or two drugs, leaving class-specific efficacy and safety incompletel…
Read on DOI →- Human
Cohort · 2026 · on Tirzepatide
Effectiveness and Safety of Tirzepatide Among Participants With Obesity With or Without Type 2 Diabetes Mellitus (T2DM)
ClinicalTrials.gov
This is a prospective, multicenter, real-world study conducted in Bangladesh to assess the effectiveness and safety of Tirzepatide compared to structured lifestyle interventions, including dietary modifications and exercise, in obese adults with or without Type 2 Diabetes Mellitus (T2DM).
View trial → - Human
RCT · 2026 · on Tirzepatide
Semaglutide Before Primary Metabolic and Bariatric Surgery in Patients With BMI 60 kg/m² or Higher
ClinicalTrials.gov
Patients with BMI 60 kg/m² or higher are the hardest operations in bariatric surgery. Thick abdominal wall, massive hepatomegaly, reduced working space, fragile fatty tissue, higher conversion and complication rates. Every bariatric surgeon knows this group. Almost no trial recruits it.
View trial → - Human
RCT · 2026 · on Tirzepatide
A Trial Within Cohort Feasibility Study Design Comparing Standard of Care Versus Weight Loss (Achieved Through Tirzepatide) for Obesity-related Hypertension in Young Adults
ClinicalTrials.gov
Hypertension is the leading risk factor for death globally, affecting approximately 30% of adults in the United Kingdom. Obesity is also a serious and ongoing epidemic, with global obesity rates having more than tripled in men and doubled in women, since 1975.
View trial → - Human
2026 · on Tirzepatide
Tirzepatide attenuates cardiac microvascular injury and ferroptosis-related lipid peroxidation in diabetic mice: endothelial responses in the context of partial PRKN silencing
Lu G, Wang X, Zhuang H, Wang X, Zhou X, Zhao G. · European journal of pharmacology
Background Diabetic metabolic stress damages the cardiac microvasculature.
Read on DOI → - Human
Case report · 2026 · on Tirzepatide
Case Report: Panic attacks after tirzepatide injection in two female patients with recurrent depressive disorder
Palm U, Backmund M, Himmerich H. · Frontiers in drug safety and regulation
Tirzepatide was introduced several years ago for the management of obesity. Its side-effect profile includes gastrointestinal symptoms and hormonal shifts similar to other glucagon-like peptide-1 receptor agonists (GLP-1RAs).
Read on DOI → - Human
2026 · on Tirzepatide
Tirzepatide safety in EudraVigilance: descriptive and disproportionality analysis of preferred terms related to suboptimal treatment outcomes and drug-use-related issues
Popa Ilie IR, Ghibu S, Butuca A, Dobrea CM, Frum A, Stoicescu L, Homorodean C, Gligor FG, Morgovan C. · BMJ open
Objective As obesity and diabetes are on the verge of an alarming growth, so is the use of tirzepatide, a novel dual glucose-dependent insulinotropic peptide/glucagon-like peptide-1 (GLP-1) receptor agonist (RA) and currently the most effective weight loss-drug.
Read on DOI → 2026 · on Tirzepatide
Tirzepatide use in adolescents with metabolic dysfunction‐associated steatotic liver disease (MASLD): A case series
Perumpail B, Tou A, Panganiban J. · JPGN reports
Open source →- Human
2026 · on Tirzepatide
Real-world observational study evaluating metabolic and kidney outcomes in patients living with chronic kidney disease and type 2 diabetes mellitus with obesity prescribed tirzepatide
Carruthers JE, Ooi XY, Goodall D, Reed J, Bedi R, McGrath A, Willicombe M, Avari P, Frankel AH. · Diabetic medicine : a journal of the British Diabetic Association
Background Obesity and type 2 diabetes mellitus (T2DM) accelerate chronic kidney disease (CKD) progression. Tirzepatide, a dual glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptor agonist, has demonstrated metabolic and potential renoprotective benefits in clinical trials.
Read on DOI → - Animal
2026 · on Tirzepatide
Tirzepatide alleviates hepatic steatosis and inflammation in MASLD partly through suppression of macrophage Dectin-1/Syk/NF-κB signaling
He Y, Ma T, Xing H, Cao X, Song F, Pan Y, Ren L. · European journal of pharmacology
Metabolic stress, hepatic lipid accumulation, and macrophage-associated sterile inflammation are closely involved in the development of metabolic dysfunction-associated steatotic liver disease (MASLD). Tirzepatide improves metabolic outcomes, but its effects on macrophage inflammatory signaling in MASLD remain unclear.
Read on DOI → - Human
Cohort · 2026 · on Tirzepatide
Dual GIP/GLP-1 receptor agonist versus selective GLP-1 receptor agonist in patients undergoing primary total knee or hip arthroplasty
Davis SC, Patel SV, Fletcher S, McLaughlin JP, Deren ME, Piuzzi NS. · European journal of orthopaedic surgery & traumatology : orthopedie traumatologie
Purpose Tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist, whereas semaglutide is selective for the GLP-1 receptor.
Read on DOI → - Human
2026 · on Tirzepatide
Tirzepatide Initiation in Lithium-Treated Bipolar Disorder: Renal Biomarker Trajectories and Lithium Safety Signals Over 12 Months in a Real-World Cohort
Rescalli MB, Fagiolini A, Carmellini P, Pinzi M, Castaldo F, Cuomo A. · Human psychopharmacology
Objective To assess early renal and lithium-related safety and 12-month renal biomarker trajectories after tirzepatide initiation in lithium-treated adults with bipolar disorder. Methods We retrospectively studied 23 adults at one centre.
Read on DOI → - Human
Cohort · 2026 · on Tirzepatide
Weight-Loss Outcomes After Sleeve Gastrectomy Versus Tirzepatide in a Minority Cohort With Severe Obesity: Results From a Propensity Score Matched Cohort
Manueli Laos EG, Fontaine-Nicola A, Serafica B, Zhang L, Layden BT, Berger R, Orda CA, Schlottmann F, Pirzada A, Masrur MA. · Clinical obesity
While GLP-1 and GIP receptor agonists like semaglutide and tirzepatide have revolutionized pharmacologic obesity treatment, metabolic and bariatric surgery (MBS) continues to demonstrate superior weight loss and cost-effectiveness.
Read on DOI → Review · 2026 · on Thymulin
Nano zinc supplementation in broiler nutrition: current evidence, mechanisms of action, and future perspectives
Rodriguez Velazquez D, Hosseintabar-Ghasemabad B, Varela Guerrero JA, Gorlov IF, Slozhenkina MI, Mosolov AA, Ondrašovičová S, Seidavi A, García Martínez JE, Rodríguez Huerta FA, Kr, et al. · Frontiers in veterinary science
Zinc is an essential trace mineral involved in numerous biological processes, including growth, antioxidant defense, immune function, and intestinal integrity in broiler chickens. Optimizing its bioavailability remains an important objective in modern poultry nutrition.
Read on DOI →- Human
Review · 2026 · on Thymulin
Targeting Leukopoiesis: Pharmacological and Biotechnological Strategies for the Treatment of Leukopenia
Baktybayeva L, Kaldybayeva AB, Sokolenko A, Tursynova B, Ten AY, Daulet G, Svambayev E, Thevis M, Yu VK, Tassibekov KS. · Biomedicines
Leukopenia remains a major clinical challenge associated with infectious diseases, oncological therapies, autoimmune disorders, and metabolic and iatrogenic conditions.
Read on DOI → - Human
2026 · on Thymulin
Thymulin restrains age-associated myeloid inflammation and enhances cancer immunotherapy
Kanemaru H, Luong S, Yamamoto Y, Mizukami Y, Ito F. · Nature communications
Chronic inflammation increases with age and contributes to cancer progression and therapeutic resistance, yet the mechanisms underlying this process remain incompletely understood.
Read on DOI → - Animal
2026 · on Thymosin Alpha-1 + Thymulin
Zinc Coordination by Thymosin β4: Structural Determinants and Functional Implications
Lachowicz JI, Congiu T, Salis A, Cesare Marincola F. · International journal of molecular sciences
Thymosin β4 (Tβ4) is a highly acidic, intrinsically disordered 43-amino-acid peptide with diverse biological functions, yet its interactions with metal ions remain poorly understood.
Read on DOI → - Human
RCT · 2026 · on Thymosin Alpha-1
A Study Evaluating Neoadjuvant Chemotherapy, Concurrent Chemoradiotherapy Combined With Dual Immune Checkpoint Blockade in Patients With Locally Advanced Non-Small Cell Lung Cancer
ClinicalTrials.gov
This study will enroll patients with locally advanced non-small cell lung cancer (NSCLC).
View trial → - Human
2026 · on Thymosin Alpha-1
A Case Report of a Multisystemic Immune-Related Adverse Event Caused by Sintilimab in Combination With Thymosin Alpha-1
Li T, Wu BL, Yu CL, Jin LY. · Clinical case reports
To report a case of a nasopharyngeal carcinoma patient who developed multisystem immune-related adverse events (irAEs) after treatment with sintilimab (PD-1 inhibitor) in combination with thymosin alpha-1 (Tα1). The patient presents with high fever, rash, interstitial pulmonary edema, and multiple organ failure.
Read on DOI → - Human
2026 · on Thymosin Alpha-1
Thymosin Alpha-1 Restores Chemotherapy-Induced Antitumor Immunity by Chaperoning a MicroRNA Ligand of TLR7 in Dendritic Cells
Wei Y, Chen J, Zhang Y, Liu Y, Zhu F, Wang X, Zhou X, Wu C, Zhang W, Chen J, Zhang Y, Pan N, Chen K, Zheng S, Yan C, Liu L, Wang L. · Cancer research
Chemotherapy induces cancer cell apoptosis and the release of apoptotic bodies (AB) that are poorly immunogenic or immunosuppressive, creating a major barrier to the success of coadministered or second-line immunotherapies.
Read on DOI →